Artis BioSolutions launched a synthetic DNA manufacturing hub in Boston using Syngoi Technologies’ enzymatic platform to shorten supply chains and support its Watertown GMP site; the company framed the hub as dual‑sourcing resiliency for advanced‑therapy clients. In parallel, Integrated DNA Technologies (a Danaher subsidiary) entered the IVD space with two Archer‑based NGS library‑preparation assays (Archer FusionPlex‑HT Dx and Archer VariantPlex‑HT Dx), designed for FFPE and low‑quality samples and aimed at clinical labs navigating IVDR and evolving regulatory pressures. Both moves respond to rising demand for localized, clinically certified nucleic‑acid supply and assay options.